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Some clinical trials have shown that high phytoestrogen intake may decrease serum concentrations 35 
of prostate-specific antigen (PSA), and phytoestrogens may also lower prostate cancer risk. It was 36 
the aim of this study to examine the relationship between the serum PSA level and urine 37 
phytoestrogen concentration in generally healthy US men. 824 men, 40+ year old without prostate 38 
cancer, who participated in the 2001-2004 NHANES surveys, were included in the analysis. The 39 
association of total PSA, free PSA, and PSA ratio [free PSA/total PSA * 100] with concentrations 40 
of isoflavones and lignans (standardized for urinary creatinine concentration) was examined using 41 
multivariable-adjusted linear and logistic regression models. The linear regression analyses showed 42 
no clear association between creatinine-standardized urinary phytoestrogen concentrations and 43 
serum total or free PSA levels or PSA ratio. However, the odds of having a PSA ratio < 15% rose 44 
from quartile 1 to quartile 4 of isoflavone excretion (odds ratio = 2.82, 95 % confidence interval 45 
1.28-6.22 for top versus bottom quartile), but there were no associations with having a PSA ratio < 46 
25%. In generally healthy US men, 40+ years old without a diagnosis of prostate cancer, urinary 47 
isoflavone and lignan concentrations were not associated with serum PSA level. 48 
49 
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Compared to the United States and Europe, the incidence of prostate cancer is lower in China and 50 
Japan. The lower incidence in Asian countries is hypothesized to be at least in part be due to the 51 
higher consumption of soy products rich in phytoestrogens in Asian countries (1). Isoflavones and 52 
lignans are the most common classes of phytoestrogens in the human diet. The most important 53 
sources of isoflavones are soybeans and other soy products, but the major sources of phytoestrogens 54 
in the US diet are doughnuts, pancakes, waffles and bread, all of which contain added soy (2). The 55 
major isoflavones are genistein, daidzein, formononentin, glycitein and biochanin-A. In 30-50% of 56 
the human population the gut microflora can metabolize daidzein to equol; o-desmethylangolensin 57 
is another intestinal metabolite formed from daidzein (90% of the human population) (3). Lignan 58 
concentrations are very high in flaxseed and pumpkin seed. Smaller amounts are found in a variety 59 
of foods including nuts and seeds, legumes, whole grain cereals, vegetables and fruits (2). 60 
Lariciresinol and pinoresinol contribute most to total lignan intake, followed by secoisolariciresinol 61 
and matairesinol (4). In the human body, these plant lignans are not bioavailable but they can be 62 
absorbed in the intestine once they are transformed into enterodiol and enterolactone (2). 63 
Phytoestrogens are excreted in the urine (2) and an estimate of alimentary intake of isoflavones can 64 
be derived from urinary concentration of isoflavones.  Several studies have shown that soy 65 
consumption correlates with urinary isoflavone excretion (5), even in spot urine (6). In a Finnish 66 
study, nutritional intake of lignans was associated with the urinary excretion of enterolignans (7). 67 
Prostate-specific antigen (PSA) is a biochemical marker secreted by the prostate that is used for the 68 
diagnosis and surveillance of prostate cancer. Generally, healthy men have a low serum level and 69 
higher serum levels of PSA are associated with both localized and advanced prostate cancer. 70 
However, PSA is organ-specific but not cancer-specific (8), such that PSA levels can be elevated 71 
either because of an enlargement or an inflammation of the prostate (9). Also, serum PSA levels are 72 
affected by age (10), body mass index (BMI) (11), ethnicity, (12) circulating levels of C-reactive 73 
protein (CRP) (13) and possibly by common drugs including statin drugs (14), thiazide diuretics 74 
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(15), nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (16). With respect to the 75 
effect of phytoestrogens, a small prospective Austrian intervention study observed a significant 76 
decrease in total PSA levels with daily administration of an isoflavone extract for one year in 77 
healthy men with elevated PSA levels (17). In another small double-blind placebo-controlled trial, 78 
the level of total PSA was lowered and the PSA ratio was increased in men diagnosed with prostate 79 
cancer who consumed bread with different phytoestrogen concentrations (18). Another randomized 80 
trial that administered isoflavone supplements showed no change in PSA concentrations (1). 81 
As reviewed above, to date there are only few studies in humans about the possible association of 82 
urine concentration or dietary intake of phytoestrogens with serum level of PSA, which yielded 83 
partly contradictory results (1, 17-19). It is currently also unclear whether the intake of 84 
phytoestrogens with a regular diet in the general population has an effect on PSA concentrations of 85 
generally healthy men. Thus, our study offered the opportunity to examine whether phytoestrogen 86 
concentration as observed in men with a normal diet were associated with PSA concentration in a 87 
large representative sample of US men. We hypothesized that men with higher concentrations of 88 
phytoestrogens in the urine have lower serum total PSA level and higher ratio of total to free PSA. 89 
 90 
Materials and methods 91 
The National Health and Nutrition Examination Survey (NHANES) is conducted by the US 92 
National Center for Health Statistics of the Centers for Disease Control and Prevention. Since 1999 93 
each year data are collected from a representative sample that covers all age groups of the civilian 94 
non-institutionalized US population over 2 month of age. The survey is unique because it includes 95 
interviews (questionnaires), physical and laboratory examinations.  96 
In the NHANES surveys of the years 2001-2002 and 2003-2004, PSA serum and phytoestrogen 97 
urine levels were measured (20). To address our study questions, our study sample included men 98 
meeting the following criteria: age 40 years or older, measured blood concentration of PSA, 99 
5 
 
measured urine concentration of phytoestrogens, never diagnosed with prostate cancer, no recent 100 
prostate biopsy, prostate examination or infection prior to venipuncture. The 2001-2002 and 2003-101 
2004 NHANES surveys included 10301 males, of which 3326 were age 40 years or older. PSA has 102 
been measured in 2701 men. 155 of them did not meet the prostate exclusion criteria. So, after 103 
subtracting those who had no phytoestrogen measurement (N=2546 as phytoestrogens were 104 
measured only in a random subsample of the NHANES populations) 824 men were eligible for our 105 
study. 106 
 107 
PSA, phytoestrogen and creatinine measurement 108 
The Access Hybritech Assay was used to measure concentrations of total and free PSA (Beckman 109 
Access, Fullerton CA). The PSA ratio was calculated by dividing the concentration of free PSA by 110 
the concentration of total PSA and multiplying by 100 (20, 21). 111 
Spot urine samples were collected in a standardized manner as described previously (22). The 112 
analysis of phytoestrogens (daidzein, o-desmethylangolensin equol, genistein, enterodiol, and 113 
enterolactone) was carried out with high performance liquid chromatography (HPLC) and tandem 114 
mass spectrometric (MS/MS) detection (20, 21). Creatinine concentration, which was used to 115 
standardize urinary phytoestrogen, was analyzed using a Jaffe rate reaction measured with a CX3 116 
analyzer (Beckman Instruments, Brea, CA) (22). For the statistical analysis, we evaluated the 117 
associations for the sum of isoflavones (daidzein, o-desmethylangolensin equol, genistein), the sum 118 
of enterolignans (enterodiol and enterolactone) and the sum of all isoflavones and enterolignans. 119 
 120 
Data collection 121 
Age, race/ethnicity, socioeconomic status, smoking status, intake of NSAID and physical activity 122 
were determined in a household interview prior to the examination. During a face-to-face interview 123 
in the mobile examination center (MEC), questions about alcohol consumption were asked. The 124 
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intake of prescribed medication such as statin drugs and thiazide diuretics was assessed by a 125 
personal interview by trained NHANES staff during a 1-month period prior to the survey date (23). 126 
Trained personnel measured body weight and height in the MEC. Standing height was measured in 127 
meters with a stadiometer. The participants were weighted in kilograms using a digital weight scale. 128 
Body mass index (BMI) was calculated by dividing the weight in kilograms by the square of the 129 
height in meters (24). CRP was measured by the latex-enhanced nephelometry method (21). 130 
 131 
Statistical analysis 132 
All statistical analyses accounted for the complex sample design by using the appropriate weights 133 
and sampling factors (25). For the characterization of the subpopulation, we computed arithmetic 134 
means of all continuous parameters and percentages of all categorical parameters. These 135 
calculations were also made by quartiles of genistein urine concentration. Creatinine is a very good 136 
parameter for the excretion performance of the kidneys and is used to determine the so called 137 
creatinine clearance as measure for the glomerular filtration (26), and both creatinine and 138 
phytoestrogen concentrations rise with the excretion performance of the kidneys. Therefore, all 139 
analyses were performed by standardizing the phytoestrogen concentration in µg/g creatinine in 140 
urine. Linear regression was used to examine the associations of total PSA and PSA ratio serum 141 
levels with phytoestrogen urine concentrations. Because both phytoestrogen concentrations in urine 142 
and PSA variables were not normally distributed in the study population, these values were 143 
transformed using the natural logarithm (14). In the linear regression we controlled for age 144 
(continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other), 145 
C-reactive protein (continuous), pain relievers (taken nearly every day for a month or longer 146 
yes/no), statin drugs (used in the past month yes/no), thiazide diuretics (used in the past month 147 
yes/no), smoking (ever smokers, never smokers), alcohol consumption (missing, abstinent, <1 drink 148 
per day, 1-2 drinks per day, e3 drinks per day), poverty-income ratio (0-0.99 = below poverty, e1 = 149 
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at or above poverty) (27), physical activity (any vigorous activities over past 30 days for at least 10 150 
minutes that caused heavy sweating or large increases in breathing or heart rate, 1 = yes, 0 = no) 151 
(28), BMI (continuous), educational level (<high school, High School Diploma (including GED 152 
[General Education Development]), >high school, refused/don’t know/missing). In linear models, 153 
where both the dependent and the independent variables have been ln-transformed, the dependent 154 
variable can be interpreted as percent changes for a one-percent increase in the independent variable 155 
while all other variables in the model are held constant. In addition to linear models, logistic 156 
regression models were used to test if there is an association between urine concentrations of 157 
phytoestrogens and abnormal levels of total PSA and PSA ratio. For the logistic regression, the 158 
outcome variable total PSA was converted into a categorical variable using 2.5 and 4.0 ng/ml as 159 
threshold values, which have been used for prostate cancer detection in different publications (29-160 
31). A lower PSA ratio is suggestive of prostate cancer. In our study, PSA ratio was converted into 161 
a categorical variable using, as proposed in some studies, 15% as threshold value (32, 33) and 25% 162 
as an alternative threshold, which was proposed in other publications (32, 33). Phytoestrogen urine 163 
concentrations were categorized into quartiles. We controlled for the above-mentioned confounders 164 
in the logistic regression models. 165 
Stata IC/ 11.2 software (College Station, Texas) was used to perform the analyses. 166 
The Institutional Review Board of the National Center for Health Statistics, Centers for Disease 167 
Control and Prevention, approved all protocols for the implementation of NHANES 2001-2004. 168 
Informed consent was obtained for all participants (14). 169 
 170 
Results 171 
Table 1 shows the baseline characteristics of the study population. Mean age of the participants was 172 
54.6 years; mean BMI was in the overweight range (28.8 kg/m2). Most men were non-Hispanic 173 
White (58%), were married (68.6%), and 47.6% of men had an education level higher than high 174 
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school or GED. Fourteen percent of the study population lived below poverty level. The majority of 175 
men were ever smokers (71.6%) and 43.5% of the men drank more than one alcoholic drink per day 176 
in the past 12 months prior to the survey date. 177 
Mean total and free PSA serum concentration were in the normal range (1.5 (standard error [SE] ± 178 
0.1) and 0.4 (± 0.1) ng/ml, respectively); mean PSA ratio was 30.2% (± 0.6%). Mean genistein, 179 
enterodiol and enterolactone concentrations were 190.4 (± 27.1), 146.9 (± 41.8) and 910.7 (± 104.7) 180 
ng/ml, respectively. 181 
In the linear regression models, the associations of phytoestrogen concentrations with total or free 182 
PSA serum levels and PSA ratio were not statistically significant (Table 2). 183 
There was no clear pattern of the association between urinary phytoestrogen concentrations and 184 
odds of having elevated total PSA concentration, and none of the associations were statistically 185 
significant (Table 3). However, the sum of isoflavones and the sum of all phytoestrogens were 186 
associated with an increased odds of having a PSA ratio < 15%, when comparing top versus bottom 187 
quartiles. For example, men in the top quartile of the sum of isoflavones had an OR = 2.82 (95% CI 188 
1.28-6.22) of having a PSA ratio < 15% compared with men in the bottom quartile. In contrast, 189 
there were no statistically significant associations between urine isoflavone levels and odds of 190 
having PSA ratio < 25%.  191 
In sub-analyses, we computed linear regressions for the subgroup of the men without limited renal 192 
function (which was defined as not having a chronic kidney disease: glomerular filtration rate 193 
e60ml/min/1.73m2; unweighted n=320; data not shown) (34). The results of the linear regressions 194 
of the subgroup were similar to the results of the linear regression of the main sample and not 195 
statistically significant.  196 
 197 
Discussion 198 
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A PSA-decreasing effect of phytoestrogens has been observed in cell cultures and mice (35-39). In 199 
LNCaP cells, genistein abrogated the stimulation of PSA by 17² -estradiol, and equol administration 200 
reduced PSA levels (35, 39). Some human feeding studies, which examined participants with 201 
pathological changes in the tissue of the prostate, have shown declines in PSA levels with 202 
phytoestrogen intake (17, 18, 40) or administration of soy milk (19), whereas another human 203 
feeding study found no significant effect of soy consumption on serum total or free PSA levels in 204 
healthy men (41). Also, in a double-blind, placebo-controlled randomized trial among men with 205 
prostate cancer, the administration of isoflavone supplements did not change PSA concentrations 206 
(42), but another soy intervention study observed a decrease of PSA concentrations (43). However, 207 
to the best of our knowledge, our study is the first effort to investigate the cross-sectional 208 
association between urinary phytoestrogen concentration and serum PSA level in a group of men of 209 
the general US population. We observed no clear association between urinary phytoestrogen 210 
concentration and having elevated total or free PSA concentration in the examined population. 211 
However, men in the top quartiles of isoflavones and the sum of all phytoestrogens, i.e., isoflavones 212 
and lignans, had an elevated odds of having a PSA ratio below 15%. However, there was no 213 
statistically significant odds ratio when using a cut point of 25%. 214 
The anticancer potential of the isoflavone tectorigenin was demonstrated on the molecular level 215 
(44) and the chemopreventive potential of genistein against prostate cancer was shown in two 216 
animal models (45). The anti prostate cancer effect of the phytoestrogen group of isoflavones could 217 
be hypothesized in the possible action of isoflavones on the androgen receptor (AR) in prostate 218 
tumor cells (19). Additionally the isoflavone genistein is able to inhibit several cancer promoting 219 
factors on the molecular level (1). A meta-analysis of 8 studies (US, Canada, Japan, China and 220 
Taiwan) reported an inverse association of soy food consumption with the risk for prostate cancer. 221 
(46) Moreover, a nested case-control study among Japanese men observed that serum daidzein, 222 
genistein and equol seemed to dose-dependently reduce prostate cancer risk (47). However, in our 223 
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study, the outcome was circulating level of PSA, which in the US has been used as a screening 224 
instrument for prostate cancer. PSA, however, is not cancer-specific; higher levels of serum PSA 225 
are also observed in benign prostate conditions such as benign prostatic hyperplasia and prostatitis.  226 
In evaluating whether phytoestrogens influence the likelihood of an abnormal PSA result, we used a 227 
PSA cut point of 4 ng/ml, which is often used as threshold value for prostate biopsy (48), and of 2.5 228 
ng/ml, which is sometimes used clinically for prostate cancer screening (29, 49), but we observed 229 
no statistically significant associations for either cut-point. In contrast, we observed an increased 230 
odds of having a PSA ratio < 15% with increasing isoflavone excretion. However, there were no 231 
associations when using a PSA ratio of 25% as a cut-off and we cannot exclude that the first 232 
observation is merely a chance finding. 233 
PSA screening is not optimal for detecting prostate cancer, with the consequence of possible 234 
overtreatment of men who have a pathological PSA but who have no prostate cancer or, on the 235 
other hand a prostate cancer that remains clinical unapparent (50, 51). Several factors also influence 236 
the PSA level. Besides inflammation of the prostate, urinary retention, ejaculation and ambulation 237 
have an influence on the PSA value (52). 238 
Compared to the data of the study of Valentín-Blasini et al. (53), phytoestrogen concentrations in 239 
this subpopulation of US men 40+ years old were in almost the same range. However, urinary 240 
levels of isoflavones of our sample were lower than measured in Vietnamese and Japanese samples 241 
(54). Thus, our results may indicate that the range of isoflavone intake in a general group of US 242 
men might be too narrow and too low to significantly affect PSA concentration in healthy men. An 243 
analysis of the Asian subgroup in our sample was not possible due to a small sample size (1.7% of 244 
the study population). On the other hand, levels of lignans of our sample were higher compared to 245 
the samples of the Asian study (54), supporting the importance of looking at lignan levels in 246 
addition to isoflavones in European and North-American societies. 247 
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The cross-sectional study design is one of the limitations of our study. To test whether 248 
phytoestrogen consumption affects PSA concentration, multiple measurements would better reflect 249 
actual PSA and phytoestrogen levels. Indeed, a decrease in the rate of rise of serum PSA levels in 250 
men with PSA recurrent disease was shown in two trials (19, 55), but a third trial did not report any 251 
association (1). However, the number of participants in these trials was limited and larger 252 
prospective studies are warranted. 253 
A further limitation is the use of spot urine samples for the determination of phytoestrogen levels. 254 
Measurements in spot urines may not be representative for the habitual nutritional intake of 255 
phytoestrogens. The half-lives of phytoestrogens are in the range of 3-10 hours (53). However, in a 256 
previous analysis of NHANES III data, urinary and serum levels of phytoestrogens showed a good 257 
correlation (daidzein r=0.72) (53). In addition, the problematic accuracy of PSA such that changes 258 
in PSA concentration over time can either be physiological or pathological has been discussed in 259 
different publications (1, 19, 56). 260 
In conclusion, the results of this study based on the 2001-2004 NHANES surveys, a population with 261 
a generally low intake of phytoestrogens compared with, e.g. Asian populations, showed no clear 262 
relationship between serum PSA level and urinary phytoestrogen concentration. We observed an 263 
increased odds of having a PSA ratio < 15% with high phytoestrogen levels, but there was no 264 
association when using a different cut-point for categorizing PSA ratio. Longitudinal studies among 265 
healthy men, preferably with multiple measurements of phytoestrogens and PSA, may be better 266 
suited to address the question whether habitual phytoestrogen intake has an effect on PSA 267 
concentration than cross-sectional studies. 268 
 269 
 270 
 271 
 272 
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Table 1. Baseline characteristics by quartiles of urine genistein concentration, men 40+ years old in NHANES 2001-2004 278 
Characteristic 
Mean / 
percentage *† 
SE of 
mean 
N=824  
Age (years) 54.6 0.4 
BMI (kg/m2) 28.8 0.3 
Race (%) 
 Non-Hispanic white 
 Non-Hispanic black 
 Hispanic 
 Other 
 
58.0 
18.5 
21.8 
1.7 
 
Education level (%)** 
 <High school 
 High school/GED 
 >High School 
 
29.4 
22.9 
47.6 
 
Living below poverty (PIR < 1) (%) 14.0  
Smoking history – ever smoker (%) 71.6  
Average number of alcoholic drinks/day –past 12 months (%)** 
 0 
 d1 
 >1 
 
32.2 
21.5 
43.5 
 
Any vigorous activity over past 30 days (%) 27.2  
Use of pain relievers (NSAIDs) nearly every day for a month or longer (%) 30.6  
Statin use, past month (%) 12.0  
Thiazide diuretic use, past month (%) 9.0  
Creatinine, urine (mg/dl) 143.6 3.1 
C-reactive protein (mg/dl) 0.4 0.1 
   
Total PSA (ng/ml) 1.5 0.1 
Free PSA (ng/ml) 0.4 0.1 
PSA ratio (%) 30.2 0.6 
   
Isoflavones   
   Daidzein (ng/ml) 318.0 46.1 
   Genistein (ng/ml) 190.4 27.1 
   o-Desmethylangolensin (ng/ml) 45.1 7.7 
   Equol (ng/ml) 21.1 5.3 
Lignans   
   Enterodiol (ng/ml) 146.9 41.8 
   Enterolactone (ng/ml) 910.7 104.7 
BMI, body mass index; GED, General Education Development; PIR, Poverty Income Ratio; SE, standard error. 279 
* Values are means or percentages unless otherwise noted. 280 
† The sum of the percentages may not always be 100 due to rounding. 281 
** Does not add up to 100% because of missing information. 282 
283 
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Table 2. Linear regression: outcome variables total PSA, free PSA and PSA ratio levels in the serum, exposure variables creatinine-284 
adjusted phytoestrogen-levels in the urine controlled for confounders†; NHANES 2001-2004 285 
Phytoestrogen‡ Beta-coefficient SE 
Change in % per 1% change in total or free 
PSA concentration of PSA ratio 
   
change in % 95% CI 
 
Total PSA concentration§ 
     Sum of isoflavones -0.008 0.026 -0.80 -5.73 to 4.39 
Sum of lignans 0.013 0.02 1.31 -2.59 to 5.36 
Sum of phytoestrogens -0.012 0.022 -1.19 -5.36 to 3.16 
Free PSA concentration 
     Sum of isoflavones -0.007 0.013 -0.7 -3.2 to 1.9 
Sum of lignans 0.0001 0.009 0.01 -1.7 to 1.8 
Sum of phytoestrogens -0.003 0.007 -0.3 -1.7 to 1.1 
PSA ratio (%)§ 
     Sum of isoflavones 0.011 0.014 1.11 -1.63 to 3.92 
Sum of lignans 0.001 0.014 0.10 -2.61 to 2.88 
Sum of phytoestrogens 0.011 0.015 1.11 -1.82 to 4.12 
CI, confidence interval; SE, standard error 286 
*P< 0.05 287 
† Adjusted for age, race/ethnicity, poverty-income-ratio, educational level, BMI, C-reactive protein, NSAIDs, statins, thiazide 288 
diuretics, smoking, alcohol-consumption, physical activity 289 
‡  Units of creatinine-adjusted phytoestrogen concentration were per 500µg/g creatinine, urine 290 
§ PSA-level units: The natural logarithm of total PSA in ng/ml, of free PSA in ng/ml and of PSA Ratio in % 291 
292 
15 
 
Table 3. Association between quartiles of urine phytoestrogen concentration* and elevated total PSA concentration or PSA ratio, 293 
NHANES 2001-2004† 294 
 Quartiles of phytoestrogen concentration   
 1 2  3  4  
 OR OR 95% CI OR 95% CI OR 95% CI p-trend 
Total PSA >2.5ng/ml   
   Sum of isoflavones 1.00 0.80 0.40,1.60 0.88 0.47,1.67 0.84 0.37,1.87 0.65 
   Sum of lignans 1.00 1.70 0.78,3.70 2.18 0.93,5.12 1.69 0.65,4.41 0.26 
   Sum of phytoestrogens 1.00 1.06 0.46,2.45 0.96 0.37,2.49 1.11 0.47,2.64 0.88 
Total PSA >4.0ng/ml   
   Sum of isoflavones 1.00 1.05 0.60,1.84 1.59 0.85,2.99 1.31 0.44,3.88 0.39 
   Sum of lignans 1.00 1.81 0.41,8.05 3.25 0.83,12.7 2.17 0.46,10.3 0.25 
   Sum of phytoestrogens 1.00 1.19 0.45,3.12 1.33 0.45,3.97 1.33 0.37,4.85 0.66 
PSA ratio <15%  
   Sum of isoflavones 1.00 1.04 0.39,2.82 1.52 0.67,3.44 2.82 1.28,6.22 0.02 
   Sum of lignans 1.00 0.45 0.12,1.76 1.02 0.35,2.95 2.30 0.88,5.99 0.06 
   Sum of phytoestrogens 1.00 2.40 0.79,7.29 1.65 0.55,4.90 3.77 1.34,10.6 0.03 
PSA ratio <25%  
   Sum of isoflavones 1.00 0.85 0.51,1.41 0.91 0.49,1.69 0.99 0.50,1.97 0.99 
   Sum of lignans 1.00 0.68 0.43,1.08 0.75 0.42,1.33 1.00 0.60,1.67 0.95 
   Sum of phytoestrogens 1.00 0.92 0.54,1.58 0.91 0.54,1.54 1.08 0.64,1.81 0.81 
CI, confidence interval. 295 
* Phytoestrogen concentration units: µg/g creatinine, urine 296 
† Adjusted for age, race/ethnicity, C-reactive protein, NSAIDs, statins, thiazide diuretics, smoking, alcohol-consumption, poverty-297 
income-ratio, physical activity, BMI, educational level 298 
 299 
 300 
301 
16 
 
References 302 
1. deVere White, RW, Tsodikov, A, Stapp, EC, et al. Effects of a high dose, aglycone-rich soy extract on 303 
prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr 304 
Cancer 2010;62: 1036-43. 305 
2. Valentin-Blasini, L, Sadowski, MA, Walden, D, et al. Urinary phytoestrogen concentrations in the 306 
U.S. population (1999-2000). J Expo Anal Environ Epidemiol 2005;15: 509-23. 307 
3. Atkinson, C, Frankenfeld, CL, and Lampe, JW. Gut bacterial metabolism of the soy isoflavone 308 
daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230: 155-70. 309 
4. Milder, IE, Feskens, EJ, Arts, IC, et al. Intake of the plant lignans secoisolariciresinol, matairesinol, 310 
lariciresinol, and pinoresinol in Dutch men and women. J Nutr 2005;135: 1202-7. 311 
5. Maskarinec, G, Singh, S, Meng, L, et al. Dietary soy intake and urinary isoflavone excretion among 312 
women from a multiethnic population. Cancer Epidemiol Biomarkers Prev 1998;7: 613-9. 313 
6. Seow, A, Shi, CY, Franke, AA, et al. Isoflavonoid levels in spot urine are associated with frequency of 314 
dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer 315 
Epidemiol Biomarkers Prev 1998;7: 135-40. 316 
7. Nurmi, T, Mursu, J, Penalvo, JL, et al. Dietary intake and urinary excretion of lignans in Finnish men. 317 
Br J Nutr 2010;103: 677-85. 318 
8. Cotran, R, V, K, and T, C. The Male Genital Tract. Robbins Pathologic Basis of Disease Sixth Edition, 319 
pp. 1011-1034. Philadelphia: W.B. Saunders Company, 1999. 320 
9. Arcangeli, CG, Ornstein, DK, Keetch, DW, et al. Prostate-specific antigen as a screening test for 321 
prostate cancer. The United States experience. Urol Clin North Am 1997;24: 299-306. 322 
10. Kristal, AR, Chi, C, Tangen, CM, et al. Associations of demographic and lifestyle characteristics with 323 
prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006;106: 320-8. 324 
11. Culp, S, and Porter, M. The effect of obesity and lower serum prostate-specific antigen levels on 325 
prostate-cancer screening results in American men. BJU Int 2009;104: 1457-61. 326 
12. He, D, Wang, M, Chen, X, et al. Ethnic differences in distribution of serum prostate-specific antigen: 327 
a study in a healthy Chinese male population. Urology 2004;63: 722-6. 328 
13. Lehrer, S, Diamond, EJ, Mamkine, B, et al. C-reactive protein is significantly associated with 329 
prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95: 961-2. 330 
14. Mondul, AM, Selvin, E, De Marzo, AM, et al. Statin drugs, serum cholesterol, and prostate-specific 331 
antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 332 
2010;21: 671-8. 333 
15. Chang, SL, Harshman, LC, and Presti, JC, Jr. Impact of common medications on serum total prostate-334 
specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 335 
2010;28: 3951-7. 336 
16. Singer, EA, Palapattu, GS, and van Wijngaarden, E. Prostate-specific antigen levels in relation to 337 
consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 338 
National Health and Nutrition Examination Survey. Cancer 2008;113: 2053-7. 339 
17. Engelhardt, PF, and Riedl, CR. Effects of one-year treatment with isoflavone extract from red clover 340 
on prostate, liver function, sexual function, and quality of life in men with elevated PSA levels and negative 341 
prostate biopsy findings. Urology 2008;71: 185-90; discussion 190. 342 
18. Dalais, FS, Meliala, A, Wattanapenpaiboon, N, et al. Effects of a diet rich in phytoestrogens on 343 
prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64: 510-344 
5. 345 
19. Pendleton, JM, Tan, WW, Anai, S, et al. Phase II trial of isoflavone in prostate-specific antigen 346 
recurrent prostate cancer after previous local therapy. BMC Cancer 2008;8: 132. 347 
20. National Health and Nutrition Examination Survey Data.  2011. Hyattsville, MD: U.S. Department of 348 
Health and Human Services, Centers for Disease Control and Prevention. National Center for Health 349 
Statistics (NCHS), Centers for Disease Control and Prevention. National Center for Health Statistics (NCHS) 350 
2011. 351 
17 
 
21. National Health and Nutrition Examination Survey Laboratory Protocol.  2011. Hyattsville, MD: U.S. 352 
Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for 353 
Health Statistics (NCHS), Centers for Disease Control and Prevention. National Center for Health Statistics 354 
(NCHS) 2011. 355 
22. Frankenfeld, CL. Dairy consumption is a significant correlate of urinary equol concentration in a 356 
representative sample of US adults. Am J Clin Nutr 2011;93: 1109-16. 357 
23. National Health and Nutrition Examination Survey Questionnaire 2011. Hyattsville, MD: U.S. 358 
Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for 359 
Health Statistics (NCHS), Centers for Disease Control and Prevention. National Center for Health Statistics 360 
(NCHS) 2011. 361 
24. National Health and Nutrition Examination Survey Examination Protocol.  2011. Hyattsville, MD: 362 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National 363 
Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. National Center for Health 364 
Statistics (NCHS) 2011. 365 
25. Welch, AA, Lund, E, Amiano, P, et al. Variability of fish consumption within the 10 European 366 
countries participating in the European Investigation into Cancer and Nutrition (EPIC) study. Public Health 367 
Nutr 2002;5: 1273-85. 368 
26. Herold, G. INNERE MEDIZIN 2002. Cologne: Gerd Herold, 2002. 369 
27. Statistics, NCfH. Analytic and Reporting Guidelines: The Third National Health and Nutrition 370 
Examination Survey, NHANES III (1988-94).  2012: National Center for Health Statistics, Centers for Disease 371 
Control and Prevention, 1996. 372 
28. National Center for Health Statisitcs, CfDCaP. 2001-2002 Data Documentation, Codebook, and 373 
Frequencies.  2012: National Center for Health Statisitcs, Centers for Disease Control and Prevention, 2004. 374 
29. Stephan, C, Miller, K, and Jung, K. Is there an optimal prostate-specific antigen threshold for 375 
prostate biopsy? Expert Rev Anticancer Ther 2011;11: 1215-21. 376 
30. Welch, HG, Schwartz, LM, and Woloshin, S. Prostate-specific antigen levels in the United States: 377 
implications of various definitions for abnormal. J Natl Cancer Inst 2005;97: 1132-7. 378 
31. Greene, KL, Albertsen, PC, Babaian, RJ, et al. Prostate specific antigen best practice statement: 2009 379 
update. J Urol 2009;182: 2232-41. 380 
32. Lacher, DA, Thompson, TD, Hughes, JP, et al. Total, free, and percent free prostate-specific antigen 381 
levels among U.S. men, 2001-04. Adv Data 2006: 1-12. 382 
33. Catalona, WJ, Partin, AW, Slawin, KM, et al. Use of the percentage of free prostate-specific antigen 383 
to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter 384 
clinical trial. JAMA 1998;279: 1542-7. 385 
34. Levey, AS, Eckardt, KU, Tsukamoto, Y, et al. Definition and classification of chronic kidney disease: a 386 
position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67: 2089-387 
100. 388 
35. Smith, S, Sepkovic, D, Bradlow, HL, et al. 3,3'-Diindolylmethane and genistein decrease the adverse 389 
effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr 2008;138: 2379-85. 390 
36. Han, HY, Wang, XH, Wang, NL, et al. Lignans isolated from Campylotropis hirtella (Franch.) Schindl. 391 
decreased prostate specific antigen and androgen receptor expression in LNCaP cells. J Agric Food Chem 392 
2008;56: 6928-35. 393 
37. Lazarevic, B, Karlsen, SJ, and Saatcioglu, F. Genistein differentially modulates androgen-responsive 394 
gene expression and activates JNK in LNCaP cells. Oncol Rep 2008;19: 1231-5. 395 
38. Bylund, A, Zhang, JX, Bergh, A, et al. Rye bran and soy protein delay growth and increase apoptosis 396 
of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000;42: 304-14. 397 
39. Lund, TD, Blake, C, Bu, L, et al. Equol an isoflavonoid: potential for improved prostate health, in 398 
vitro and in vivo evidence. Reprod Biol Endocrinol 2011;9: 4. 399 
40. Lazarevic, B, Boezelijn, G, Diep, LM, et al. Efficacy and safety of short-term genistein intervention in 400 
patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, 401 
double-blind Phase 2 clinical trial. Nutr Cancer 2011;63: 889-98. 402 
18 
 
41. Jenkins, DJ, Kendall, CW, D'Costa, MA, et al. Soy consumption and phytoestrogens: effect on serum 403 
prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in 404 
hyperlipidemic men. J Urol 2003;169: 507-11. 405 
42. Izumi, T, Piskula, MK, Osawa, S, et al. Soy isoflavone aglycones are absorbed faster and in higher 406 
amounts than their glucosides in humans. J Nutr 2000;130: 1695-9. 407 
43. Maskarinec, G, Morimoto, Y, Hebshi, S, et al. Serum prostate-specific antigen but not testosterone 408 
levels decrease in a randomized soy intervention among men. Eur J Clin Nutr 2006;60: 1423-9. 409 
44. Thelen, P, Seseke, F, Ringert, RH, et al. [Pharmacological potential of phytoestrogens in the 410 
treatment of prostate cancer]. Urologe A 2006;45: 195-6, 197-201. 411 
45. Lamartiniere, CA, Cotroneo, MS, Fritz, WA, et al. Genistein chemoprevention: timing and 412 
mechanisms of action in murine mammary and prostate. J Nutr 2002;132: 552S-558S. 413 
46. Yan, L, and Spitznagel, EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 414 
2005;117: 667-9. 415 
47. Ozasa, K, Nakao, M, Watanabe, Y, et al. Serum phytoestrogens and prostate cancer risk in a nested 416 
case-control study among Japanese men. Cancer Sci 2004;95: 65-71. 417 
48. Porter, MP, Stanford, JL, and Lange, PH. The distribution of serum prostate-specific antigen levels 418 
among American men: implications for prostate cancer prevalence and screening. Prostate 2006;66: 1044-419 
51. 420 
49. Lin, K, Lipsitz, R, Miller, T, et al. Benefits and harms of prostate-specific antigen screening for 421 
prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149: 422 
192-9. 423 
50. Chou, R, Croswell, JM, Dana, T, et al. Screening for Prostate Cancer; A Review of the Evidence for 424 
the U.S. Preventive Services Task Force. Ann Intern Med 2011;155: 762-771. 425 
51. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann 426 
Intern Med 2008;149: 185-91. 427 
52. Tchetgen, MB, and Oesterling, JE. The effect of prostatitis, urinary retention, ejaculation, and 428 
ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24: 283-291. 429 
53. Valentin-Blasini, L, Blount, BC, Caudill, SP, et al. Urinary and serum concentrations of seven 430 
phytoestrogens in a human reference population subset. J Expo Anal Environ Epidemiol 2003;13: 276-82. 431 
54. Kunisue, T, Tanabe, S, Isobe, T, et al. Profiles of Phytoestrogens in Human Urine from Several Asian 432 
Countries. J Agric Food Chem 2010;58: 9838-46. 433 
55. Hussain, M, Banerjee, M, Sarkar, FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr 434 
Cancer 2003;47: 111-7. 435 
56. Sighinolfi, MC, Micali, S, De Stefani, S, et al. Retrospective descriptive analysis of the physiological 436 
kinetics of prostate-specific antigen in men older than 75 years. Asian J Androl 2009;11: 493-7. 437 
 438 
 439 
19 
 
